Charleston, S.C., July 20, 2005 -- QualiLife Pharmaceuticals, Inc. announces the acceptance of its expanded 2005 clinical trial of Zestra ^TM by the National Institutes of Health (NIH). This Phase 3 type study will evaluate the efficacy and safety of Zestra^TM compared to placebo oil in 200 women diagnosed with acquired mixed interest/desire/arousal/orgasm disorders in conditions of home use in conjunction with sexual activities. The Zestra^TM study is the only registered study to directly address women's sexual problems.

The study is a randomized, placebo-controlled, double-blind, parallel design trial. Primary efficacy assessment will be the subjects' assessments of "successful and satisfactory" sexual encounters as recorded in a diary (FSEP©). Secondary evaluations of efficacy will include the other diary questions, a subject self assessment questionnaire (Female Sexual Function Index (FSFI)®), two global assessment questions (GAQ), a treatment satisfaction questionnaire (WITS©), the Beck Depression Inventory, the Dyadic Adjustment Scale (DAS), a consumer testing survey (QualiLife Consumer Testing Survey (QCTS©), a distress scale (Female Sexual Distress Scale (FSDS)©), sexual encounter frequency and drop-out rates.

The Zestra^TM study description can be viewed at www.ClinicalTrials.gov by entering any of the following search terms: female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder or Zestra. The International Committee of Medical Journal Editors (ICJME) has established a requirement that all clinical trials be entered in a public registry before the onset of patient enrollment, as a condition of consideration for publication. QualiLife intends to update the trial data as the study progresses and to publish the results in a prominent peer-reviewed journal.

Zestra^TM femi
'"/>

Contact: Emily Ross
eross@kupperparker.com
Kupper Parker Communications
20-Jul-2005

Page: 1 2 3 4
Related medicine news :

1. National quality agenda, payment reform, care integration keys to improving quality, patient safety
2. National Academies Advisory -- June 8 public briefing on LANL groundwater protection
3. Story tips from the Department of Energys Oak Ridge National Laboratory, May 2007
4. National Autism Conference slated for June
5. National Academy of Sciences Institute of Medicine report calls for more dairy foods at school
6. Annual meeting of the National Academy of Sciences
7. National experts and nonprofit organizations call to end FDA user fees and to improve drug safety
8. National Institute of Dental and Craniofacial Research activities
9. National addiction treatment leaders to meet at first NIATx Summit
10. K-State National Agricultural Biosecurity Center director speaker at AAAS Biosecurity Symposium
11. National Inventors Hall of Fame announces 2007 inductees